Large gap with delayed quotes
|
Last quote
07/03/2025
-
23:00:00
|
Bid
07/03/2025 -
18:59:59
|
Bid Volume |
Ask
07/03/2025 -
18:59:59
|
Ask Volume |
|---|---|---|---|---|
|
29.80
+0.36
(
+1.22% )
|
29.79
|
100 |
29.84
|
1,500 |
Analysis date: 01.07.2025
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 17.06.2025.
Interest
Very weak
Very weak
One star since 24.06.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 27.06.2025 at a price of 29.96.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The forty day technical trend is negative since 17.06.2025.
4wk Rel Perf
-15.24%
-15.24%
The four-week dividend-adjusted underperformance versus SP500 is 15.24%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 07.02.2025.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.49%.
Mkt Cap in $bn
2.69
2.69
With a market capitalization between $2 & $8bn, CRINETICS PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
-0.48
-0.48
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-8.16
-8.16
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-3.88%
-3.88%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
12
12
Over the last seven weeks, an average of 12 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
119
119
For 1% of index variation, the stock varies on average by 1.19%.
Correlation
0.47
0.47
46.61% of stock movements are explained by index variations.
Value at Risk
8.80
8.80
The value at risk is estimated at USD 8.80. The risk is therefore 30.97%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
04.02.2025
04.02.2025